| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT04858958 Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation |
Trial completed |
| 2026-08-15 | NCT04858958 Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation |
Enrollment increased: 30 -> 90 participants |
| 2026-08-15 | NCT04858958 Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation |
date change Completion moved earlier: 2026-02-28 -> 2025-06-25 |
| 2026-08-14 | NCT04853342 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With… |
date change Primary completion pushed: 2026-01 -> 2026-12 |
| 2026-08-14 | NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… |
date change Primary completion pushed: 2026-03 -> 2027-03 |
| 2026-08-14 | NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… |
date change Completion pushed: 2026-03 -> 2027-03 |
| 2026-08-14 | NCT06416410 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… |
date change Primary completion pushed: 2026-09-30 -> 2029-09-30 |
| 2026-08-14 | NCT06416410 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… |
date change Completion pushed: 2027-02-28 -> 2030-08 |
| 2026-08-14 | NCT05009329 A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C… |
date change Primary completion pushed: 2026-05 -> 2026-08 |
| 2026-08-14 | NCT05276726 A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11… |
date change Primary completion pushed: 2026-02 -> 2027-08 |
| 2026-08-14 | NCT05276726 A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11… |
date change Completion pushed: 2026-02 -> 2027-08 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04853342 | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With… | Non-small Cell Lung Carcinoma | Recruiting |
| NCT06416410 | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… | Advanced Non-squamous Non-small-cell Lung Cancer | Recruiting |
| NCT06956001 | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With… | EGFR | Recruiting |
| NCT06970639 | A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus… | NSCLC Patients With Brain Metastasis | Recruiting |
| NCT07010419 | A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant… | NSCLC | Recruiting |
| NCT03787992 | Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic… | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic… | KRAS P.G12C | Recruiting |
| NCT05466149 | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic… | NSCLC | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05276726 | A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11… | Non-small Cell Lung Cancer | Recruiting |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… | KRAS P.G12C | Recruiting |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid… | Advanced Colorectal Cancer | Active, Not Recruiting |
| NCT05009329 | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C… | NSCLC | Active, Not Recruiting |
| Phase 1 | |||
| NCT06955988 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303… | Locally Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting |